Fc Fusion Protein Engineering for Selective Regulatory T-Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies targeting immunomodulatory receptors on T cells, such as anti-CTLA-4 antibodies, face challenges in optimizing anti-tumor efficacy due to varying isotypes affecting Fc receptor binding, leading to inconsistent depletion of regulatory T cells and effector T cells, thus limiting therapeutic effectiveness.
Innovation Solution
Engineering the Fc region of Fc fusion proteins, such as anti-CTLA-4 antibodies, to enhance binding to activating Fc receptors, specifically targeting regulatory T cells at tumor sites to selectively deplete them, thereby enhancing the endogenous immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapies use standard Fc regions in immunomodulatory Fc fusion proteins, then the proteins can bind to immunomodulatory receptors on T cells, but the anti-tumor efficacy is limited due to inconsistent depletion of regulatory T cells and effector T cells
Solution Approach 1:
The patent applies local quality by engineering specific modifications to the Fc region to create differential binding properties. The Fc region is modified to have high affinity for activating FcγRs (enhancing effector cell recruitment) while maintaining or having reduced affinity for inhibitory FcγRs. This localized modification of binding characteristics at different FcγR interaction sites enables selective depletion of regulatory T cells while preserving effector T cell function, thereby resolving the contradiction between reliable anti-tumor efficacy and selective depletion capability.
Solution Approach 2:
The patent employs parameter changes by systematically varying the affinity parameters of the Fc region for different FcγR subtypes. Through amino acid substitutions and glycosylation modifications in the Fc region, the binding affinity constants (Kd values) are optimized to achieve strong binding to activating FcγRs (like FcγRIIIa) and weak binding to inhibitory FcγRs. This parameter optimization enables the Fc fusion protein to selectively deplete regulatory T cells while maintaining effector T cell activity, thus improving anti-tumor efficacy with enhanced selectivity.
2Reliability
If the Fc region is engineered to enhance binding to activating Fc receptors, then selective depletion of regulatory T cells is improved, but the complexity of protein engineering increases
Solution Approach 1:
The patent applies segmentation by dividing the Fc region engineering into modular components: (1) specific amino acid substitutions at defined positions (e.g., L234A, L235A, N297Q), (2) glycosylation site modifications, and (3) domain-specific optimizations. These segmented engineering strategies allow systematic optimization of FcγR binding properties without requiring complete redesign of the entire Fc region, thereby reducing engineering complexity while achieving reliable selective depletion of regulatory T cells.
Solution Approach 2:
The patent uses parameter changes to simplify the engineering process by focusing on specific critical parameters rather than comprehensive optimization. Key parameters such as affinity for FcγRIIIa (targeting activating receptors) and affinity for FcγRIIB (inhibitory receptor) are independently optimized through targeted amino acid substitutions. This parameter-focused approach reduces the complexity of Fc region engineering by concentrating modifications on critical binding interfaces rather than attempting global optimization of all FcγR interactions.
3Productivity
If immunomodulatory Fc fusion proteins deplete both regulatory T cells and effector T cells, then the immune response is suppressed, but if they selectively deplete only regulatory T cells, then the engineering requirements become more stringent
Solution Approach 1:
The patent applies local quality by creating differential binding properties at specific FcγR interaction sites within the Fc region. The Fc region is engineered to have enhanced binding to activating FcγRs (promoting effector cell recruitment and immune response) while maintaining reduced binding to inhibitory FcγRs (avoiding effector cell depletion). This localized differentiation of binding characteristics enables selective depletion of regulatory T cells through activating receptor engagement, thereby enhancing immune response with precise manufacturing specificity.
Solution Approach 2:
The patent employs parameter changes to achieve selective depletion by optimizing the ratio of binding affinities for different FcγR subtypes. The affinity parameter for activating FcγRs (Kd ~10^-8 to 10^-9 M) is enhanced relative to the affinity for inhibitory FcγRs (Kd ~10^-7 M or higher). This parameter differentiation enables the Fc fusion protein to selectively engage activating receptors on effector cells while avoiding inhibitory receptor-mediated depletion, thereby achieving high productivity in immune response enhancement with controlled manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach selectively reduces regulatory T cells at tumor sites, boosting the immune response and improving anti-tumor efficacy by increasing the ratio of effector T cells to regulatory T cells, resulting in enhanced tumor rejection and growth inhibition.
Implementation Method 1
enhance the binding of the Fc region to an activating Fc receptor
Data Source
AI summary
The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.